{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:15:12Z","timestamp":1794881712551,"version":"4.9.1"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cladribine (CLAD), an immune reconstitution therapy for active multiple sclerosis (MS), can reduce intrathecal antibody production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>In this study, we investigated the long-term impact of oral CLAD on protective antibody levels, essential for preventing infections and immune defense.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Observational long-term study including a cohort of 15 CLAD-treated MS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We longitudinally studied the humoral immunity to seven common pathogens (measles, mumps, varicella-zoster virus, diphtheria and tetanus toxin, rubella, hepatitis B virus (HBV)) and absolute immunoglobulin G (IgG) levels prior to CLAD treatment (baseline, BL; 12\/2017\u201303\/2020) and after an average of 73\u2009months (long-term) follow-up to explore the impact on pre-existing IgG. At long-term, we assessed IgG response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to evaluate potential inhibitory effects on the formation of new immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We found no CLAD associated loss of humoral immunity over up to 7\u2009years. Pathogen-specific IgG antibodies were present in 60%\u2013100% and 67%\u2013100% of patients at BL and long-term, respectively. We found no decline in absolute IgG levels 73\u2009months after starting CLAD treatment. Patients who received subsequent anti-CD20 treatment had significantly lower SARS-CoV-2 antibody levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011) compared to the rest of the cohort, which developed adequate anti-SARS-CoV-2 IgG. One patient had a clinically silent tick-borne encephalitis (TBE) infection mounting appropriate IgG and IgM. No severe COVID-19 cases occurred, and no new safety concerns were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These long-term data suggest that CLAD treatment does not impact preexisting humoral immunity or antibody production toward novel antigens. Our results support the positive long-term safety profile of the drug.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251357275","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T13:30:30Z","timestamp":1754314230000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term impact of oral cladribine on humoral immunity in multiple sclerosis"],"prefix":"10.1177","volume":"18","author":[{"given":"Marc","family":"Messner","sequence":"first","affiliation":[{"name":"Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, member of European Reference Network EpiCARE, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7262-942X","authenticated-orcid":false,"given":"Michael","family":"Unterhofer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, member of European Reference Network EpiCARE, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Strauss","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, member of European Reference Network EpiCARE, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Mink","sequence":"additional","affiliation":[{"name":"Central Medical Laboratories, Feldkirch, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Cadamuro","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Oberkofler","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hitzl","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Optometry, Paracelsus Medical University, Salzburg, Austria"},{"name":"Research Program Experimental Ophthalmology and Glaucoma Research, Paracelsus Medical University, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wipfler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, member of European Reference Network EpiCARE, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, member of European Reference Network EpiCARE, Salzburg, Austria"},{"name":"Neuroscience Institute, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-5595","authenticated-orcid":false,"given":"Tobias","family":"Moser","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, member of European Reference Network EpiCARE, Ignaz-Harrer-Stra\u00dfe 79, Salzburg 5020, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104491"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577966"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-022-00931-4"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732020-00003"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70005-5"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113116"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200048"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1327672"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231211077"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51206"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02859-x"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110380"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.006"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103765"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8830-y"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111584"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103931"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1380654"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint14040075"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103560"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221092092"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.19766"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104156"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00172.x"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02249-9"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01964245"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251357275","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251357275","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251357275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:16:01Z","timestamp":1754550961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251357275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"alternative-id":["10.1177\/17562864251357275"],"URL":"https:\/\/doi.org\/10.1177\/17562864251357275","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251357275"}}